Q-omics provides the consensus-scored PDE2A-AS2 profile across patient tissues and cancer cell-line models. PDE2A-AS2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PDE2A-AS2 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, PDE2A-AS2 RNA expression shows 14,020 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, HNSC, and TGCT as cancer lineages where PDE2A-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE2A-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE2A-AS2 survival associations across molecular data types. PDE2A-AS2 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE2A-AS2 RNA expression–survival associations across cancer types. High PDE2A-AS2 expression shows unfavorable associations in UVM, ACC, LAML, THYM and STAD, but favorable associations in LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PDE2A-AS2 RNA expression.
This table summarizes PDE2A-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PDE2A-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE2A-AS2 shows lower tumor expression in COAD, KICH and LUAD and higher tumor expression in HNSC, KIRC and BRCA. The HNSC box plot shows higher PDE2A-AS2 RNA expression in tumor versus normal tissue (log2 FC = +0.849, t-test p < 0.001).
This table shows molecular features associated with PDE2A-AS2 in patient tissues and cancer cell lines. In patient samples, PDE2A-AS2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
